If they indeed include ALCL in BLA (not a given), I think the fda will use the advisory panel to slam the ALCL single arm - tiny sample results but in the end the fda will approve both indications. That may create a buying opp. after the panel meeting.
The ALCL indication adds about $50mm in rev./yr. JMworthlessO